BRAF inhibitors such as vemurafenib or encorafenib (tyrosine kinase inhibitors specific to the ATP-binding domain of BRAF V600E) have been tested in patients with CRC or melanoma with BRAF V600E mutations. The gene discussed is BRAF; the disease is melanoma.